Globus Medical, Inc.
GMED · Price history
Price at last available close
$82.91
+$8.01 (+10.69%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Globus Medical, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products.
How they make money
Globus Medical develops, manufactures, and markets musculoskeletal implants and surgical instruments. The company generates revenue primarily through the sale of these products to hospitals and ambulatory surgery centers, supported by a direct sales force and independent distributors, as well as through robotic navigation and imaging platform services.
Products & services
Musculoskeletal implants, surgical instruments, robotic guidance and navigation systems (ExcelsiusGPS), intraoperative imaging (Excelsius3D), and surgical planning software (Surgimap).
Brands & revenue mix
Robotic guidance and navigation system for minimally invasive and open procedures.
Separate brand revenue is not available in this research.Source
Intraoperative and image-guided robotic navigation solution.
Separate brand revenue is not available in this research.Source
Surgical planning software platform.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company does not rely on any single customer for more than 10% of its total revenue as of the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Contract Manufacturers — The company utilizes various third-party contract manufacturers for the production of certain components and finished goods.Source
Competitors
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
64
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
82
Strong
Financial Strength
78
Business Quality / Moat
100
Management
99
Growth Quality
40
Risk / Durability
74
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
75
Fair
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
74/100
Building Historical Record
Model Score 74/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is mixed across its combined quality, valuation and risk inputs. Review the category scores to identify what is helping or hurting the result.
At today’s price, the WSS valuation framework currently reads as relatively attractive.
The model outlook is currently positive.
- •Balance-sheet / debt profile scores strongly
- •Valuation scores attractively
- •Recent buyback activity is present
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for GMED
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can GMED maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is GMED's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is GMED likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is GMED's valuation discount tied to a temporary concern or to a longer-term business risk?
Essential Investment Snapshot
Wall Street Score
64
Opportunity Score
75
Market Cap
$11.13B
P/E Ratio
18.9
EPS
$3.97
52-Week High
$101.40
52-Week Low
$56.21
Beta
0.96
Intrinsic Value
$152.84
Analyst Target
$100.00
Shares Outstanding
137.2M
Total Revenue
$3.14B
Total Debt
$111.2M
Dividend
No current dividend
Liquidation Value / Share
$34.75
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for GMED
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on GMED.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Engineering-driven innovation and rapid product development cycle.
- +Strong surgeon-focused product design and feedback loop.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Intense competition in the medical device industry.
- −Regulatory risks associated with product approvals and compliance.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
64
Sep 28, 2026
Change
Unchanged
Current Score
64
Oct 1, 2026
Category Changes
GMED score was unchanged.
Projected Score
Projected Score
63
Projected Change
-0.8 points
Preliminary comparable-period financial changes suggest decline of approximately 0.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$82.91
Model Intrinsic Value
$152.84
Difference
−$69.94
-45.8% vs IV
Margin of Safety
45.8%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.14B | $2.94B | $2.52B | $1.57B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $989.1M | $957.8M | $1.04B | $548.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $2.16B | $1.98B | $1.48B | $1.02B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $184.8M | $185.0M | $163.8M | $124.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $1.35B | $1.32B | $981.0M | $643.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $1.50B | $1.50B | $1.32B | $887.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $876.3M | $729.9M | $473.7M | $346.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $652.7M | $479.8M | $166.0M | $133.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $4.2M | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $665.0M | $609.9M | $120.7M | $165.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $129.5M | $72.0M | $17.7M | $42.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $535.5M | $537.9M | $103.0M | $122.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $3.97 | $3.98 | $0.76 | $1.09 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 135M | 135M | 136M | 113M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 138M | 137M | 138M | 115M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$789.6M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$1.10
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-8.2%
Cash Change
+121.3%
Margin Change
-8.0 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
What Weakened
- Margins contracted
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels. Pressure indicators included EPS growth, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 5.9%. EPS declined 26.2%. Cash increased 121.3%. Total debt declined 8.2%. Net income margin declined by 8.0 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
37
Smart Money
37
Number of Gurus
3
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
2 Healthcare Technology Stocks for a Digital Health Boom
Globus Medical (GMED) is a Top-Ranked Value Stock: Should You Buy?
Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026
Reasons to Add Globus Medical Stock to Your Portfolio Now
Rumor Mill · GMED
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial